Toxicology – N-Acetylcysteine (NAC)

Core Concept

N-acetylcysteine (NAC) is the specific antidotal treatment for clinically important acetaminophen (paracetamol) poisoning.

Its major protective effect is restoration of glutathione, allowing detoxification of the reactive acetaminophen metabolite NAPQI.

NAC is most effective when started early, but an important principle is:

Late presentation is not a reason to withhold NAC when acetaminophen-related hepatic injury is suspected.

Normal Acetaminophen Metabolism

At therapeutic exposure, most acetaminophen undergoes hepatic conjugation through:

• Glucuronidation
• Sulfation

A smaller fraction is oxidized by cytochrome P450 enzymes, particularly CYP2E1, producing:

N-acetyl-p-benzoquinone imine (NAPQI)

NAPQI is highly reactive.

Role of Glutathione

Under normal conditions:

NAPQI + glutathione → nontoxic conjugates

Therefore, only a small amount of reactive NAPQI normally remains available to injure hepatocytes.

What Happens in Overdose

Following a sufficiently large exposure:

Conjugation pathways become overwhelmed → proportion metabolized to NAPQI increases → glutathione stores fall

Once detoxification capacity becomes inadequate:

NAPQI binds cellular proteins → mitochondrial oxidative injury → hepatocyte necrosis

The centrilobular region of the liver is particularly vulnerable.

How NAC Works

NAC protects through several mechanisms.

1. Glutathione restoration

NAC provides cysteine, a rate-limiting substrate for glutathione synthesis.

This restores the liver’s ability to detoxify NAPQI.

2. Alternative sulfur substrate

Early after overdose, NAC can favor safer acetaminophen metabolism through sulfation-related pathways.

3. Direct reducing effects

NAC has antioxidant and reducing properties that may limit oxidative injury.

4. Benefit in established liver injury

Even after most acetaminophen has been metabolized, NAC can still provide benefit through effects on:

• Oxidative stress
• Mitochondrial function
• Hepatic microcirculation
• Tissue oxygen delivery

This explains why NAC remains useful in late presenters with acetaminophen-induced acute liver failure.

Timing of NAC

NAC provides its greatest protection when started within approximately 8 hours of a significant acute overdose.

However:

Do not interpret the 8-hour concept as a treatment cutoff.

Patients presenting later can still benefit substantially.

Do Not Delay NAC When Risk Is Significant

If a potentially toxic acute ingestion occurred and the acetaminophen concentration will not be available before the period when early NAC is most effective, treatment is commonly started while awaiting results.

NAC can subsequently be discontinued if appropriate evaluation demonstrates that continued treatment is unnecessary.

Rumack–Matthew Nomogram

The nomogram estimates hepatotoxicity risk after a specific type of exposure:

A single, acute acetaminophen ingestion with a reasonably known ingestion time.

A properly timed serum acetaminophen concentration is plotted against time since ingestion.

If the concentration reaches the applicable treatment line, NAC is indicated.

When the Nomogram Can Be Used

The classic nomogram is designed for concentrations obtained from approximately:

4 to 24 hours after a single acute ingestion

A level obtained too early may not represent peak absorption.

When the Nomogram Should NOT Be Used

Do not apply the Rumack–Matthew nomogram to:

• Unknown ingestion time
• Repeated supratherapeutic ingestion
• Chronic excessive use
• Staggered ingestion over an extended period
• Patients already presenting with established hepatic injury

These situations require different clinical assessment.

Modified-Release Acetaminophen

Extended- or modified-release products can produce delayed or prolonged absorption.

Similarly, coingestion of drugs that slow gastrointestinal motility may alter absorption.

A single early concentration can therefore occasionally be misleading.

Selected patients require repeat acetaminophen concentrations rather than relying on one measurement.

Unknown Time of Ingestion

When the time cannot be established reliably, the nomogram cannot be interpreted correctly.

Assessment should instead incorporate:

• Detectable acetaminophen concentration
• AST and ALT
• Clinical history
• Evidence of hepatic injury
• Other laboratory abnormalities

When clinically meaningful exposure remains possible, NAC is generally favored while the evaluation continues.

Repeated Supratherapeutic Ingestion

Repeated excessive acetaminophen use differs from a single acute overdose.

The nomogram is not valid.

Evaluation generally includes:

• Serum acetaminophen
• AST
• ALT
• Exposure history
• Risk factors and clinical condition

NAC is appropriate when laboratory findings or exposure circumstances suggest clinically important acetaminophen toxicity.

Late Presentation

A patient may present after the serum acetaminophen concentration has become very low or undetectable.

This does not exclude acetaminophen toxicity.

If the patient has compatible acute hepatic injury after a credible exposure:

NAC should be started or continued despite an undetectable acetaminophen concentration.

Clinical Course of Acetaminophen Poisoning

The clinical course is traditionally divided into stages, although individual patients may not follow them precisely.

Early phase

Possible:

• Nausea
• Vomiting
• Malaise
• Diaphoresis

Some patients are completely asymptomatic.

Developing hepatic injury

Over the next day or several days:

• AST/ALT rise
• Right upper quadrant discomfort may develop
• INR may increase

Severe toxicity

Possible:

• Massive aminotransferase elevation
• Coagulopathy
• Hypoglycemia
• Lactic/metabolic acidosis
• Encephalopathy
• Acute kidney injury
• Multiorgan failure

Recovery

Survivors may undergo substantial hepatic regeneration over subsequent days to weeks.

Acute Liver Failure

Severe acetaminophen toxicity can produce:

• Coagulopathy
• Encephalopathy
• Hypoglycemia
• Lactic acidosis
• Acute kidney injury
• Cerebral edema in advanced acute liver failure

These patients require intensive care and early involvement of a liver-transplant center when appropriate.

NAC should generally continue while clinically significant acetaminophen-associated liver failure persists.

Laboratory Evaluation

Depending on presentation, useful investigations include:

• Serum acetaminophen concentration
• AST
• ALT
• INR/PT
• Bilirubin
• Creatinine
• Electrolytes
• Glucose

In severe illness, additional testing may include:

• Blood gas
• Lactate
• Phosphate
• Serial renal and hepatic studies

Serum Acetaminophen Concentration

Interpret the concentration in context.

Important questions include:

• Was this a single acute ingestion?
• Is the ingestion time reliable?
• Was the sample drawn at least several hours afterward?
• Was a modified-release preparation involved?
• Were gastrointestinal-motility-slowing drugs coingested?
• Is there already hepatic injury?

The number alone does not answer these questions.

Oral vs Intravenous NAC

NAC can be administered:

• Orally
• Intravenously

Both routes are effective when used appropriately.

Modern practice frequently uses IV NAC because it is easier to administer in patients with:

• Persistent vomiting
• Altered consciousness
• Severe poisoning
• Acute liver failure
• Inability to tolerate oral medication

The preferred route also depends on local protocols and product availability.

Old Oral Protocol

Historically, oral NAC was administered using a prolonged multi-dose regimen lasting several days.

Although effective, treatment duration is no longer viewed as an inflexible clock.

Modern practice increasingly emphasizes clinical and laboratory stopping criteria.

Modern IV NAC

IV NAC is now widely available and routinely used.

The older statement that an approved IV formulation was unavailable in the United States is obsolete.

Several IV administration protocols exist internationally.

Protocol choice varies by:

• Country
• Institution
• Poison center
• Clinical circumstances

Exact dosing should follow the current local protocol.

Do Not Give Oral NAC Formulation IV

The historical practice of administering an oral/inhalational NAC formulation intravenously is obsolete where approved IV NAC is available.

Only an appropriate formulation intended for parenteral use should be administered intravenously.

Duration of Treatment

A fixed protocol duration should not automatically determine when NAC stops.

At the expected end of treatment, reassess:

• Acetaminophen concentration
• AST/ALT
• INR
• Clinical condition

In severe poisoning also consider:

• Lactate
• Acid-base status
• Renal function
• Evidence of improving or worsening liver failure

When NAC Should Be Continued

Continue beyond the standard protocol when there is evidence such as:

• Persistent measurable acetaminophen
• Rising or significantly abnormal aminotransferases
• Worsening hepatic dysfunction
• Persistent clinically important coagulopathy
• Ongoing acute liver failure

Treatment is continued until appropriate stopping criteria are satisfied.

When NAC Can Usually Be Stopped

In general, discontinuation requires a reassuring combination of:

• Acetaminophen no longer clinically significant
• Improving hepatic injury
• Improving prognostic markers
• Clinically stable patient

Exact stopping criteria should follow current toxicology protocols.

IV NAC Reactions

IV NAC can cause non-IgE-mediated anaphylactoid reactions.

Possible manifestations include:

• Flushing
• Pruritus
• Urticaria
• Angioedema
• Wheezing
• Bronchospasm
• Hypotension

These reactions are related partly to histamine release and infusion conditions.

Anaphylactoid Reaction ≠ Permanent NAC Allergy

An important modern distinction:

A reaction to IV NAC does not automatically mean that NAC can never be given again.

Because NAC may be life-saving, management depends on reaction severity.

Treatment can include:

• Temporarily interrupting or slowing the infusion
• Antihistamine treatment for appropriate cutaneous reactions
• Standard emergency treatment for severe reactions
• Restarting NAC cautiously when clinically necessary after stabilization

Toxicology consultation is appropriate for severe reactions.

Risk of IV Reactions

Interestingly, anaphylactoid reactions are more frequent in patients with lower acetaminophen concentrations.

This may relate to acetaminophen itself reducing histamine-mediated reactions.

A history of asthma may also increase risk.

Oral NAC Adverse Effects

The most common problems are:

• Nausea
• Vomiting
• Unpleasant sulfur odor/taste

Antiemetic treatment may improve tolerance.

Medication-Error Risk

IV NAC has historically been associated with medication errors because treatment protocols may involve:

• Multiple infusion phases
• Different concentrations
• Weight-based calculations
• Different fluid volumes

Modern simplified protocols in some centers aim partly to reduce these errors.

Careful pharmacy preparation and protocol verification remain important.

Fluid Considerations

Standard IV preparation volumes may be excessive for:

• Small children
• Patients with fluid restriction
• Certain critically ill patients

Fluid volume should therefore be individualized while preserving the required NAC treatment.

Massive Acetaminophen Poisoning

Exceptionally large exposures may present early with:

• Profound metabolic acidosis
• Elevated lactate
• Altered mental status
• Mitochondrial dysfunction

This can occur before classic hepatic failure develops.

These cases require immediate toxicology consultation.

Selected severe cases may require intensified antidotal management and consideration of extracorporeal therapy.

Hemodialysis

Acetaminophen is dialyzable, but routine overdose does not require hemodialysis because NAC is highly effective.

Dialysis is reserved for selected extraordinary poisonings, particularly massive exposures associated with severe metabolic abnormalities and clinical deterioration.

Because dialysis can also remove NAC, antidotal therapy must be managed appropriately during extracorporeal treatment.

Activated Charcoal

Activated charcoal can reduce acetaminophen absorption when given to appropriately selected patients after a significant recent ingestion.

It should only be used when:

• Expected benefit is meaningful
• The substance is adsorbable
• Airway protection is adequate
• No contraindication exists

Modern evidence does not support automatically increasing the NAC dose simply because activated charcoal was administered.

Alcohol and Acetaminophen

The relationship between ethanol and acetaminophen toxicity is complex.

Acute ethanol exposure

Ethanol competes for CYP2E1 and can temporarily reduce NAPQI formation.

Chronic heavy alcohol use

Chronic alcohol exposure may increase CYP2E1 activity and is often associated with nutritional or glutathione-related vulnerabilities.

However:

Standard assessment and appropriate NAC treatment should not be withheld simply because a patient uses alcohol.

Pregnancy

The historical FDA Category B classification is obsolete.

Acetaminophen crosses the placenta, and maternal toxicity can threaten both mother and fetus.

NAC should be administered when indicated during pregnancy.

NAC itself also crosses the placenta.

Maternal stabilization and prevention of hepatic injury are central priorities.

Newborn Management

The older recommendation that every infant delivered to a mother receiving NAC automatically requires a complete independent NAC course is not a universal modern rule.

Neonatal management should instead depend on:

• Timing and severity of maternal poisoning
• Timing of delivery
• Neonatal acetaminophen exposure
• Neonatal laboratory findings
• Clinical condition

Neonatology and toxicology input is appropriate.

Other Proposed Uses

Older literature proposed NAC for several non-acetaminophen poisonings, including:

• Carbon tetrachloride
• Chloroform
• Amanita mushroom poisoning
• Monochloroacetic acid
• Selected chemotherapy toxicities

Evidence varies considerably.

NAC should not automatically be regarded as a specific antidote for these exposures.

Amanita Mushroom Poisoning

NAC has sometimes been incorporated into supportive regimens for severe amatoxin-associated hepatic injury.

However, it does not replace established management such as:

• Aggressive supportive care
• Specialist toxicology input
• Consideration of silibinin where available
• Early transplant-center involvement in progressive acute liver failure

Its precise independent benefit in amatoxin poisoning remains uncertain.

Non-Acetaminophen Acute Liver Failure

IV NAC has also been studied in some forms of acute liver failure unrelated to acetaminophen.

Potential benefit appears dependent on etiology and stage of illness.

This is a specialist hepatology/critical-care use rather than a general-purpose poisoning antidote.

Important Modernization of the Older Source

• NAC remains the specific antidotal therapy for acetaminophen poisoning.
• Its major early action is restoration of glutathione needed to detoxify NAPQI.
• NAC also provides benefit after hepatic injury has begun, so late presentation does not make treatment futile.
• The Rumack–Matthew nomogram applies only to an appropriately timed concentration after a single acute ingestion with a reasonably known time.
• The nomogram should not be applied to repeated supratherapeutic, staggered, or unknown-time exposures.
• Modified-release preparations and delayed absorption may require repeat acetaminophen concentrations.
• An undetectable acetaminophen level does not exclude late acetaminophen-induced liver injury.
• IV NAC is now widely available; historical use of oral/inhalational formulations intravenously is obsolete.
• Modern treatment duration is determined by clinical and laboratory stopping criteria, not simply completion of a fixed number of hours.
• NAC should continue when acetaminophen remains clinically significant or hepatic injury is ongoing.
• IV NAC reactions are usually anaphylactoid rather than classic IgE allergy and often do not permanently contraindicate further NAC.
• Severe acetaminophen-induced acute liver failure requires early transplant-center consideration.
• Hemodialysis is reserved for selected massive poisonings rather than routine overdose.
• NAC therapy remains appropriate during pregnancy when indicated.
• A newborn does not automatically require a complete NAC course solely because the mother received NAC.
• Historical pregnancy letter categories are obsolete.

Key Points

• Acetaminophen overdose → excess NAPQI → glutathione depletion → hepatocellular injury.
• NAC replenishes glutathione and detoxifies NAPQI.
• NAC works best when started early, especially within the first several hours, but remains beneficial in late toxicity and acute liver failure.
• Do not delay NAC in a high-risk exposure while waiting for delayed laboratory results.
• Use the Rumack–Matthew nomogram only for a single acute ingestion with a reliable time.
• Do not use the nomogram for unknown-time, staggered, or repeated supratherapeutic ingestion.
• Serial acetaminophen levels may be necessary when absorption is delayed.
• A low or undetectable acetaminophen concentration does not rule out late hepatic toxicity.
• Follow AST/ALT, INR, acetaminophen concentration, renal function, glucose, and clinical status as appropriate.
• Do not stop NAC merely because the standard protocol time has elapsed if hepatic injury or measurable acetaminophen persists.
• IV NAC can cause anaphylactoid reactions, but these often can be treated while preserving necessary antidotal therapy.
• Severe acute liver failure requires intensive supportive care and early consideration of liver-transplant evaluation.